Evidence map›Paper›PMID 41175304›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon.

Marta Solange Camarinha Ramos Costa, Ana Caroline Alves da Costa, Esdras Edgar Batista Pereira, Diana Feio da Veiga Borges Leal, Antônio André Conde Modesto, Elisa da Silva Menezes, Rita de Cássia Calderaro Coelho, Sidney Emanuel Batista Dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta Solange Camarinha Ramos CostaOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil. marta.solange.costa@gmail.com.
Ana Caroline Alves da CostaOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Esdras Edgar Batista PereiraOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Diana Feio da Veiga Borges LealOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Antônio André Conde ModestoOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Elisa da Silva MenezesOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Rita de Cássia Calderaro CoelhoOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Sidney Emanuel Batista Dos SantosOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Marianne Rodrigues FernandesOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
Ney Pereira Carneiro Dos SantosOncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil. npcsantos.ufpa@gmail.com.ORCID http://orcid.org/0000-0001-8087-7037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTaxanes are drugs commonly used in the treatment of breast cancer. Despite their proven therapeutic efficacy, they can induce severe toxicities, which can be investigated by pharmacogenomics. In this context, the aim of this study was to investigate 26 molecular biomarkers in 17 pharmacogenes (CYP2C8, ABCB1, CYP1A1, CYP1B1, CYP19A1, CYP3A5, ERCC1, ERBB2, VEGFA, ERCC2, MDM2, MTHFR, RAD51, SOD2, TP53, TANC1 and XRCC1), in women with Breast Cancer undergoing Taxane treatment in the Brazilian Amazon region.

methodsThis study was carried out with 279 women diagnosed with BC, undergoing antineoplastic chemotherapy treatment based on Taxanes (Docetaxel and Paclitaxel), in Brazilian Amazon region. 26 pharmacogenetic markers located in 17 genes involved in the metabolic pathway of Taxanes and related toxicities were selected. Single nucleotide variants were genotyped by allelic discrimination using TaqMan OpenArray Genotyping technology.

resultsThe study population showed significant associations of Taxane toxicities with ten variants of nine genes: CYP1A1, CYP19A1, CYP3A5, ERCC1, VEGFA, ERCC2, MTHFR, TANC1 and XRCC1. Notably, variants in TANC1 and XRCC1, previously associated with radiotoxicity, were also implicated in Taxane-induced toxicities. The study demonstrated that novel biomarkers may be important for investigating Taxane-induced toxicities in breast cancer.

conclusionsThese findings represent a unique contribution to the field, potentially enabling more precise chemotherapy selection, particularly for populations such as Amazonian women.

Indexed as

Antineoplastic AgentsBiomarkers, TumorBreast NeoplasmsTaxoidsAdultAgedBrazilDocetaxelFemaleHumansMiddle AgedPaclitaxelPolymorphism, Single NucleotideAntineoplastic AgentsBiomarkers, TumorDocetaxelPaclitaxelTaxoidsBreast cancerChemotherapyPharmacogenomicsTaxanesToxicity

Identifiers

PMID41175304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.